NCT07251946 is a clinical trial in Bladder Cancer, sponsored by Lian Yang.

Who is sponsoring NCT07251946?

NCT07251946 is sponsored by Lian Yang.

What condition does NCT07251946 study?

NCT07251946 studies Bladder Cancer.

Is NCT07251946 still recruiting?

NCT07251946 is currently completed. Last updated 26 November 2025.

Last reviewed 2025-11-26 · How we verify

NCT07251946

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of Multiphasic CT-based Delta-Radiomics Model for Predicting Postoperative Recurrence Risk in Bladder Cancer

Completed Last updated 26 November 2025

What this trial tests

trial in Bladder Cancer in 316 participants. Completed in 31 March 2023.

Timeline

1 August 2019

Primary endpoint
31 March 2023

31 March 2023

Quick facts

Lead sponsor	Lian Yang
Status	Completed
Study type	OBSERVATIONAL
Enrollment	316
Start date	1 August 2019
Primary completion	31 March 2023
Estimated completion	31 March 2023
Sites	1 location across China

Conditions studied

Bladder Cancer — all drugs for Bladder Cancer →

Sponsor

Lian Yang

Who can join

18 and older, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This retrospective study included 316 bladder cancer patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting

Other Lian Yang trials

Trials by the same sponsor.

NCT07274436 — The Clinical Value of Deep Learning-Based Reconstruction Techniques in Cardiac MRI Scanning · recruiting
NCT07274423 — Clinical Value of Deep Learning Reconstruction Technology in Ankle MRI · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07251946 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lian Yang
Last refreshed: 26 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07251946.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing